Skip to main content
. Author manuscript; available in PMC: 2016 May 23.
Published in final edited form as: Acad Emerg Med. 2015 Sep 16;22(10):1172–1180. doi: 10.1111/acem.12767

Table 3.

Differences in Drug Treatment Utilization at 3-Month Follow-up by Study Group, Baseline Versus 3-Month Follow-up (N = 633)

Control Group (n = 327)
 Treatment Group (n = 306)
Baseline,

%		 3-Month
Follow-up,

%		 Baseline –
3-month
Follow-up,

Δ1% (95% CI)		 Baseline,

%		 3-Month
Follow-up,

%		 Baseline –
3-Month
Follow-up,

Δ2% (95% CI)		 Control Group –
Treatment Group,
Δ1% – Δ2%
(95% CI)
Currently receiving
treatment		 8.6 11.9 −3.4 (−6.7 to 0.3) 8.5 13.7 −5.2 (−8.8 to −1.3) 1.8 (−3.5 to 6.8)
Received treatment
in the past 3
months, but not
currently receiving
treatment		 5.5 5.5 0.0 (−3.1 to 3.1) 6.5 4.6 2.0 (−1.6 to 5.6) −2.0 (−6.5 to 2.4)
Contacted treatment
only in the past 3
months		 6.4 2.5 4.0 (1.0 to 7.3) 4.6 2.3 2.3 (−0.3 to 4.9) 1.7 (−2.4 to 6.1)
No contact, no
treatment in past 3
months		 79.5 80.1 −0.6 (−4.6 to 3.7) 80.4 79.4 1.0 (−4.2 to 6.2) −1.6 (−8.3 to 5.5)

Note: Participants who responded with “don’t know” or “refuse to answer” were considered to be in the “No contact, no treatment” category at 3 months. The sum of categories at 3-month follow-up should then equal 100% by study arm (e.g., currently receiving treatment, received treatment past 3 months, contacted only, and no contact or treatment in past 3 months. All CIs are calculated using the bootstrap method with 1,000 resamples.